RICHMOND, British Columbia, Dec. 13, 2010 (GLOBE NEWSWIRE) -- BioCurex (OTCBB:BOCX) has announced that it will host a shareholder update conference call on Wednesday, Dec. 15, 2010, at 4:10 p.m. EST (3:10 p.m. CST). The call will begin with a 10-minute presentation followed by a Q&A session.
Participation in the call is open to all interested parties. Participants may use the following phone numbers to take part in the call. Within the U.S. and Canada dial (Toll Free): 877-407-0782. International participants can dial: 201-689-8567. A live webcast will also be available at http://www.investorcalendar.com/IC/CEPage.asp?ID=162778. A replay will be made available. To access the replay, visit www.BioCurex.com.
About BioCurex, Inc.
BioCurex, Inc. is a biotechnology company that is developing products based on patented and proprietary technology in the area of cancer diagnostics. The technology identifies a universal cancer marker known as RECAF.
RECAF is a molecule that is present on cancer cells but not detected in significant levels on healthy cells or benign tumor cells. It is the receptor for alpha-fetoprotein and is classified as an oncofetal antigen due to its presence on both fetal and malignant tissues. This characteristic makes RECAF a more accurate indicator of cancer than most current tumor markers.
BioCurex is commercializing its technology through licensing arrangements with companies that develop and market diagnostic tests for the large automated clinical laboratory setting, through development and marketing of non-automated clinical laboratory tests, through development of rapid, point-of-care test formats, and through marketing of its OncoPet RECAF test for cancer in companion animals.
BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories (NYSE:ABT) and with Alere (NYSE:ALR), formerly Inverness Medical Innovations.
For further information on these agreements visit: .
For more information about the Company, please visit www.BioCurex.com.
For more information about OncoPet Diagnostics Inc., please visit: www.OncoPetDiagnostics.com.
Forward-Looking Statements
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.
CONTACT: BioCurex, Inc. Antonia Haughton (604) 207 9150 http://www.biocurex.com Investor Awareness, Inc. Investor Relations Contact: Tony Schor James Foy (847) 945 2222 http://www.investorawareness.com
